Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Mijn nieuwsbrieven
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Amerika
Nevro Corp
Nieuws
Nevro Corp
NVRO
NYS
: NVRO
| ISIN: US64157F1030
26/04/2024
11,32 USD
(-2,58%)
(-2,58%)
26/04/2024
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
17 april 2024 ·
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
· Persbericht
28 februari 2024 ·
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
· Persbericht
21 februari 2024 ·
Nevro Enters Into Cooperation Agreement With Engaged Capital
· Persbericht
21 februari 2024 ·
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
· Persbericht
1 februari 2024 ·
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
· Persbericht
29 januari 2024 ·
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
· Persbericht
18 januari 2024 ·
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
· Persbericht
17 januari 2024 ·
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
· Persbericht
9 januari 2024 ·
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
· Persbericht
4 januari 2024 ·
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
· Persbericht
1 november 2023 ·
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
· Persbericht
4 oktober 2023 ·
Nevro to Report Third Quarter 2023 Financial Results
· Persbericht
18 september 2023 ·
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy
· Persbericht
23 augustus 2023 ·
Nevro Announces Participation in Upcoming Investor Conferences
· Persbericht
16 augustus 2023 ·
New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
· Persbericht
1 augustus 2023 ·
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
· Persbericht
13 juli 2023 ·
Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
· Persbericht
12 juli 2023 ·
Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
· Persbericht
27 juni 2023 ·
Nevro to Report Second Quarter 2023 Financial Results
· Persbericht
23 juni 2023 ·
Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe